PharmaZell is a newly established company that has taken over Noveon s business of active pharmaceutical ingredients (APIs) and intermediates in May 2006. This management buy-out enables PharmaZell to become entirely focused on the pharmaceutical industry. The name PharmaZell was chosen indicating the return to the roots of the business in the 1950s. In June 2007 Pharmazell acquired from Sandoz a controlling stake in GEA Pharmaceutical located in Copenhagen, Denmark. GEA s broad capabilities in finished dosage form development and the experience in controlled substances complement now the portfolio of services and products that Pharmazell offers to its customers.

PharmaZell s mission is to provide high quality ingredients and services at competitive prices to its customers. This is achieved by combining the best of two worlds with manufacturing and development bases in Europe and India. The business is determined to grow through continued investments in new and existing product and service areas.

PharmaZell offers to its clients standard and custom made APIs and intermediates as well as all chemical, pharmaceutical development services and regulatory activities required to bring a pharmaceutical product to the market.

PharmaZell serves its customers through a worldwide sales organization including its own employees as well as agents. The sales team is committed to provide fast and competent solutions to the requests of our clients.

PharmaZell operates cGMP sites in Chennai/India, Copenhagen/ Denmark and Raubling/Germany with a total of about 330 employees. An additional site is currently being developed in Vizag/India. The combination of European and Indian sites generates flexibility in manufacturing capacities and attractive cost structures.

PharmaZell s quality assurance and regulatory departments ensure full regulatory and GMP compliance. PharmaZell regularly passed FDA inspections during the last 20 years. All sites have been inspected by European authorities and GMP certificates are available for all APIs. GEA s quality assurance and regulatory departments ensure full regulatory compliant dossiers and GMP compliant production of clinical trial batches.

PharmaZell develops innovative processes for APIs and Intermediates through its R&D groups that cover all scales from laboratory to commercial production. Through the acquisition of GEA, PharmaZell provides fully vertically integrated development programmes from API to finished dosage form including regulatory documentation, procedures and strategies.

 
PROFILE
PharmaZell brochure PharmaZell Brochure
PharmaZell brochure PharmaZell Company